proof: infigratinib as first-line therapy in patients with advanced cca
Published 4 years ago • 134 plays • Length 4:28Download video MP4
Download video MP3
Similar videos
-
1:45
proof 301: infigratinib in advanced cca
-
7:27
infigratinib for cca
-
2:31
efficacy of second-line chemotherapy in advanced cca with fgfr2 fusions
-
1:00:01
webinar: targeting the fgfr pathway: infigratinib in cholangiocarcinoma
-
2:15
phase 2 trial of chemotherapy plus gefitinib as first-line treatment for lung adenocarcinoma
-
0:57
pros in advanced cisplatin-ineligible uc: first-line ev ± pembrolizumab
-
2:41
leap-011: exploring first-line pembrolizumab lenvatinib for advanced urothelial carcinoma
-
2:17
dr. roychowdhury on fgfr inhibitor infigratinib in cholangiocarcinoma
-
2:04
design and results of persist-1 trial of pacritinib for myelofibrosis
-
0:54
role of patient advocacy in clinical trial design
-
9:27
post-hoc analysis of sequential afatinib and osimertinib in nsclc patients
-
2:38
trophy-u-01 cohort 3: sacituzumab govitecan pembrolizumab for patients with muc
-
1:31
risk-adjusted safety analysis of pacritinib for patients with mf
-
1:34
patriot ii: 1l maintenance avelumab in advanced uc
-
37:32
clinical trials in cholangiocarcinoma:abc experience - dr. john bridgewater
-
0:45
advancing uterine cancer management
-
1:52
afib research alert: prevalence before cardiac surgery & concomitant ablation factors
-
53:09
webinar: tas 120 clinical trial in cholangiocarcinoma updates